FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Biologicals / New equine antitoxins to botulinum neurotoxins serotypes A a...
Biologicals : journal of the International Association of Biological Standardization2012; 40(4); 240-246; doi: 10.1016/j.biologicals.2012.03.004

New equine antitoxins to botulinum neurotoxins serotypes A and B.

Abstract: Hyperimmune monovalent antitoxins to botulinum neurotoxin serotypes A and B have been produced by immunizing horses with newly developed formalin toxoids. After primary immunization, horses developed acceptable prophylactic antibody titers (1-5 IU/mL). Three horses received additional toxoid booster injections to induce hyperimmune antibody titers with antitoxin-A and antitoxin-B titers reaching peaks of approximately 2000 IU/mL and 150-625 IU/mL, respectively. Titers were quantified throughout the process by antigen-capture ELISA and by in-vivo neutralization. ELISA titers and neutralization titers correlated (R² ∼0.62-0.92), however, unique correlations between in-vitro and in-vivo titers were observed for each horse. Monovalent antitoxin pools were made by combining plasma that had been collected twice via plasmaphoresis several months after primary immunization. Neutralizing units were established for each pool relative to the current US and WHO reference standards. Titers were determined at the L(+)/10 and L(+)/40 toxin dose for Toxin types A and B, respectively, and U.S. and international units were assigned to each monovalent antitoxin. Avidity of the new Anti-A pool was equivalent to the WHO Anti-A reference at the L(+), L(+)/10 and L(+)/30 dose. Each monovalent plasma pool failed to cross-neutralize other botulinum neurotoxin serotypes indicating a high degree of specificity of each antitoxin for the toxin serotype used during immunization.
Published by Elsevier Ltd.
Get Full Text
Publication Date: 2012-05-05 PubMed ID: 22560800PubMed Central: PMC3393819DOI: 10.1016/j.biologicals.2012.03.004Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • N.I.H.
  • Extramural
  • Research Support
  • U.S. Gov't
  • P.H.S.

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research article presents a new study on the production of hyperimmune monovalent antitoxins to botulinum neurotoxin serotypes A and B, achieved by immunizing horses with newly developed formalin toxoids. Post immunization, increased antibody titers were observed, with peaks at approximately 2000 IU/mL and between 150 to 625 IU/mL, respectively. Testing established the specificity of each antitoxin for the toxin serotype used during immunization.

Immunization Procedure and Resulting Antibody Titers

  • The study started by immunizing horses with new formalin toxoids that were designed for botulinum neurotoxin serotypes A and B.
  • Following this primary immunization, it was found that the horses developed prophylactic antibody titers, measuring between 1-5 IU/mL which are within acceptable limits.
  • The process was then taken a step further, with three horses receiving more toxoid booster injections. This was done to induce hyperimmune antibody levels.
  • After these additional injections, antitoxin-A and antitoxin-B levels peaked at around 2000 IU/mL and ranged from 150-625 IU/mL respectively.

Measurement Methods and Results

  • The method of quantification of titers was two-fold: by an antigen-capture ELISA (Enzyme-Linked Immunosorbent Assay), which is a commonly used method to measure antibodies in biological fluids, and by in-vivo neutralization, a method that determines the effectiveness of the antitoxins in a living organism.
  • The researchers observed a strong correlation between the ELISA titers and neutralization titers, with an R² (a measure of how close the data are to the fitted regression line) value ranging from about 0.62 to 0.92.
  • However, the relation between the in-vitro (ELISA) and in-vivo (neutralization) titers was unique to each horse.

Preparation of Monovalent Antitoxin Pools

  • Plasma, collected twice via plasmaphoresis (a process that filters the blood and removes harmful antibodies) months after the primary immunization, was combined to make monovalent antitoxin pools.
  • The neutralizing units for each pool were established relatively to the current US and the World Health Organization (WHO) reference standards.
  • Each pool was found to have a very high degree of specificity for the toxin serotype used during the initial immunization, indicating that the pools were unable to cross-neutralize other botulinum neurotoxin serotypes.

Cite This Article

APA
Li D, Mattoo P, Keller JE. (2012). New equine antitoxins to botulinum neurotoxins serotypes A and B. Biologicals, 40(4), 240-246. https://doi.org/10.1016/j.biologicals.2012.03.004

Publication

Biologicals : journal of the International Association of Biological Standardization
ISSN: 1095-8320
NlmUniqueID: 9004494
Country: England
Language: English
Volume: 40
Issue: 4
Pages: 240-246

Researcher Affiliations

Li, D
  • US FDA, CBER, Office of Vaccines Research and Review, Bethesda, MD 20892, USA.
Mattoo, P
    Keller, J E

      MeSH Terms

      • Animals
      • Antitoxins / biosynthesis
      • Antitoxins / immunology
      • Botulinum Toxins / immunology
      • Botulinum Toxins, Type A / immunology
      • Enzyme-Linked Immunosorbent Assay
      • Horses / immunology
      • Mice
      • Neutralization Tests
      • Plasmapheresis

      Grant Funding

      • Y01 AI006153 / NIAID NIH HHS
      • Y01 AI006153-04 / NIAID NIH HHS
      • YI-AI-6153-01 / NIAID NIH HHS

      References

      This article includes 37 references
      1. van Ermengem E. Classics in infectious diseases. A new anaerobic bacillus and its relation to botulism. E. van Ermengem. Originally published as "Ueber einen neuen anaëroben Bacillus und seine Beziehungen zum Botulismus" in Zeitschrift für Hygiene und Infektionskrankheiten 26: 1-56, 1897.. Rev Infect Dis 1979 Jul-Aug;1(4):701-19.
        pubmed: 399378
      2. LAMANNA C. Toxicity of bacterial exotoxins by the oral route.. Science 1960 Apr 15;131(3407):1100-1.
        pubmed: 13853549doi: 10.1126/science.131.3407.1100google scholar: lookup
      3. Shapiro RL, Hatheway C, Swerdlow DL. Botulism in the United States: a clinical and epidemiologic review.. Ann Intern Med 1998 Aug 1;129(3):221-8.
        pubmed: 9696731doi: 10.7326/0003-4819-129-3-199808010-00011google scholar: lookup
      4. Leuchs J. Beitrage zur Kenntnis des Toxins und Antitoxins des Bacellus botulinus. Z Hyg Infeckt Med Mikrobiol Immunol Virol 1910;65:55–84.
      5. Burke GS. Notes on Bacillus botulinus.. J Bacteriol 1919 Sep;4(5):555-570.1.
        pmc: PMC378820pubmed: 16558852doi: 10.1128/jb.4.5.555-570.1.1919google scholar: lookup
      6. Bengtson IA. Preliminary note on a toxin producing anaerobe isolated from the larvae of Lucilia caesar. Pub Hlth Rep 1922;37:164–170.
      7. Arnon SS, Schechter R, Maslanka SE, Jewell NP, Hatheway CL. Human botulism immune globulin for the treatment of infant botulism.. N Engl J Med 2006 Feb 2;354(5):462-71.
        pubmed: 16452558doi: 10.1056/nejmoa051926google scholar: lookup
      8. FIOCK MA, CARDELLA MA, GEARINGER NF. STUDIES ON IMMUNITY TO TOXINS OF CLOSTRIDIUM BOTULINUM. IX. IMMUNOLOGIC RESPONSE OF MAN TO PURIFIED PENTAVALENT ABCDE BOTULINUM TOXIOD.. J Immunol 1963 May;90:697-702.
        pubmed: 14054890
      9. Jones RG, Liu Y, Rigsby P, Sesardic D. An improved method for development of toxoid vaccines and antitoxins.. J Immunol Methods 2008 Aug 20;337(1):42-8.
        pubmed: 18571196doi: 10.1016/j.jim.2008.05.009google scholar: lookup
      10. Byrne MP, Smith TJ, Montgomery VA, Smith LA. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate.. Infect Immun 1998 Oct;66(10):4817-22.
        pmc: PMC108595pubmed: 9746584doi: 10.1128/iai.66.10.4817-4822.1998google scholar: lookup
      11. Siegel LS. Evaluation of neutralizing antibodies to type A, B, E, and F botulinum toxins in sera from human recipients of botulinum pentavalent (ABCDE) toxoid.. J Clin Microbiol 1989 Aug;27(8):1906-8.
        pmc: PMC267699pubmed: 2768475doi: 10.1128/jcm.27.8.1906-1908.1989google scholar: lookup
      12. Keller JE. Characterization of new formalin-detoxified botulinum neurotoxin toxoids.. Clin Vaccine Immunol 2008 Sep;15(9):1374-9.
        pmc: PMC2546675pubmed: 18667637doi: 10.1128/cvi.00117-08google scholar: lookup
      13. FULTHORPE AJ. Clostridium botulinum types A and B toxin-antitoxin reactions.. J Hyg (Lond) 1955 Jun;53(2):180-95.
        pmc: PMC2217823pubmed: 14392316doi: 10.1017/s0022172400000656google scholar: lookup
      14. National Research Council. Guide for the care and use of laboratory animals. Washington: National Academy Press; 1996.
      15. BOWMER EJ. PREPARATION AND ASSAY OF THE INTERNATIONAL STANDARDS FOR CLOSTRIDIUM BOTULINUM TYPES A, B, C, D AND E ANTITOXINS.. Bull World Health Organ 1963;29(6):701-9.
        pmc: PMC2555097pubmed: 14107742
      16. Reed LJ, Muench H. A simple method of estimating fifty percent endpoints. Am J Hyg 1938;27:493–497.
      17. Glenny AT, Walpole GS. Detection and Concentration of Antigens by Ultrafiltration, Pressure Dialysis, etc. with Special Reference to Diphtheria and Tetanus Toxins.. Biochem J 1915 Jun;9(2):298-308.1.
        pmc: PMC1258581pubmed: 16742375doi: 10.1042/bj0090298google scholar: lookup
      18. Glenny AT, Pope CG, Waddington H, Wallace H. Comparison between in vitro and in vivo methods of testing diphtheria antitoxin. J Pathol 1925;28:463–482.
      19. Glenny AT. INSOLUBLE PRECIPITATES IN DIPHTHERIA AND TETANUS IMMUNIZATION.. Br Med J 1930 Aug 16;2(3632):244-5.
        pmc: PMC2450349pubmed: 20775638doi: 10.1136/bmj.2.3632.244google scholar: lookup
      20. Barr M, Glenny AT. Some practical applications of immunological principles.. J Hyg (Lond) 1945 Apr;44(2):135-42.
        pmc: PMC2234754pubmed: 20475719doi: 10.1017/s0022172400035968google scholar: lookup
      21. BARR M. The formation of abnormal diphtheria antitoxin in the early stages of immunisation.. J Pathol Bacteriol 1951 Oct;63(4):557-70.
        pubmed: 14898361doi: 10.1002/path.1700630402google scholar: lookup
      22. Buer AW. A method for production of high-titre tetanus serum. Acta Path 1946;23:293–298.
      23. FREUND J, THOMSON KJ. Antibody formation and sensitization with the aid of adjuvants.. J Immunol 1948 Nov;60(3):383-98.
        pubmed: 18890196
      24. Glenny A, Barr M. The Precipitation of Diphtheria toxoid by potash alum. J Path Bact 1931;34:131–135.
      25. Cox JC, Premier RR, Finger W, Hurrell JG. A comparison of enzyme immunoassay and bioassay for the quantitative determination of antibodies to tetanus toxin.. J Biol Stand 1983 Apr;11(2):123-8.
        pubmed: 6345547doi: 10.1016/s0092-1157(83)80035-3google scholar: lookup
      26. Cox JC, Liefman CE, Premier RR, Chandler HM, Herrington RW, Middleton HD, Hurrell JG. Immune response and reactions to various dose regimens for raising hyperimmune antisera in sheep.. Vet Immunol Immunopathol 1984 Aug;7(1):65-72.
        pubmed: 6485249doi: 10.1016/0165-2427(84)90028-xgoogle scholar: lookup
      27. Wells PW, Gilmour NJ, Burrells C, Thompson DA. A serological comparison of Pasteurella haemolytica vaccines containing different adjuvants.. Res Vet Sci 1979 Sep;27(2):248-50.
        pubmed: 523817
      28. Siegel LS. Human immune response to botulinum pentavalent (ABCDE) toxoid determined by a neutralization test and by an enzyme-linked immunosorbent assay.. J Clin Microbiol 1988 Nov;26(11):2351-6.
        pmc: PMC266891pubmed: 3235662doi: 10.1128/jcm.26.11.2351-2356.1988google scholar: lookup
      29. Bengtson IA. STANDARDIZATION OF BOTULISM ANTITOXINS.. Am J Public Health (N Y) 1921 Apr;11(4):352-7.
        pmc: PMC1353790pubmed: 18010472doi: 10.2105/ajph.11.4.352google scholar: lookup
      30. BOWMER EJ. PREPARATION AND ASSAY OF THE INTERNATIONAL STANDARDS FOR CLOSTRIDIUM BOTULINUM TYPES A, B, C, D AND E ANTITOXINS.. Bull World Health Organ 1963;29(6):701-9.
        pmc: PMC2555097pubmed: 14107742
      31. Clayton MA, Clayton JM, Brown DR, Middlebrook JL. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli.. Infect Immun 1995 Jul;63(7):2738-42.
        pmc: PMC173366pubmed: 7790092doi: 10.1128/iai.63.7.2738-2742.1995google scholar: lookup
      32. Glenny AT, Hopkins BE, Pope CG. Further notes on modification of diphtheria toxin by formaldehyde. J Path Bacteriol 1924;27:261–270.
      33. Glenny AT, Wallace U. The titration of diphtheria toxin by the flocculation method. J Path Bacteriol 1925;28:317–331.
      34. Hatheway CH, Snyder JD, Seals JE, Edell TA, Lewis GE Jr. Antitoxin levels in botulism patients treated with trivalent equine botulism antitoxin to toxin types A, B, and E.. J Infect Dis 1984 Sep;150(3):407-12.
        pubmed: 6481185doi: 10.1093/infdis/150.3.407google scholar: lookup
      35. Yu YZ, Zhang SM, Wang WB, Du Y, Zhu HQ, Wang RL, Zhou XW, Lin JB, Wang S, Yu WY, Huang PT, Sun ZW. Development and preclinical evaluation of a new F(ab')₂ antitoxin against botulinum neurotoxin serotype A.. Biochimie 2010 Oct;92(10):1315-20.
        pubmed: 20600570doi: 10.1016/j.biochi.2010.06.010google scholar: lookup
      36. Held DM, Shurtleff AC, Fields S, Green C, Fong J, Jones RG, Sesardic D, Buelow R, Burke RL. Vaccination of rabbits with an alkylated toxoid rapidly elicits potent neutralizing antibodies against botulinum neurotoxin serotype B.. Clin Vaccine Immunol 2010 Jun;17(6):930-6.
        pmc: PMC2884417pubmed: 20410329doi: 10.1128/cvi.00493-09google scholar: lookup
      37. Jones RG, Corbel MJ, Sesardic D. A review of WHO International Standards for botulinum antitoxins.. Biologicals 2006 Sep;34(3):223-6.
        pubmed: 16490362doi: 10.1016/j.biologicals.2005.11.009google scholar: lookup

      Citations

      This article has been cited 8 times.
      1. Shi DY, Lu JS, Mao YY, Liu FJ, Wang R, Du P, Yu S, Yu YZ, Yang ZX. Characterization of a novel tetravalent botulism antitoxin based on receptor-binding domain of BoNTs.. Appl Microbiol Biotechnol 2023 May;107(10):3205-3216.
        doi: 10.1007/s00253-023-12515-2pubmed: 37058230google scholar: lookup
      2. Ben David A, Barnea A, Torgeman A, Diamant E, Dor E, Schwartz A, Rosen O, Caspi N, Saraf M, Lerer E, Adar Y, Lupo E, Toister E, Zichel R. Immunologic and Protective Properties of Subunit- vs. Whole Toxoid-Derived Anti-Botulinum Equine Antitoxin.. Vaccines (Basel) 2022 Sep 14;10(9).
        doi: 10.3390/vaccines10091522pubmed: 36146601google scholar: lookup
      3. Rosenfeld R, Alcalay R, Zvi A, Ben-David A, Noy-Porat T, Chitlaru T, Epstein E, Israeli O, Lazar S, Caspi N, Barnea A, Dor E, Chomsky I, Pitel S, Makdasi E, Zichel R, Mazor O. Centaur antibodies: Engineered chimeric equine-human recombinant antibodies.. Front Immunol 2022;13:942317.
        doi: 10.3389/fimmu.2022.942317pubmed: 36059507google scholar: lookup
      4. Rasetti-Escargueil C, Popoff MR. Antibodies and Vaccines against Botulinum Toxins: Available Measures and Novel Approaches.. Toxins (Basel) 2019 Sep 12;11(9).
        doi: 10.3390/toxins11090528pubmed: 31547338google scholar: lookup
      5. Matak I. Evidence for central antispastic effect of botulinum toxin type A.. Br J Pharmacol 2020 Jan;177(1):65-76.
        doi: 10.1111/bph.14846pubmed: 31444910google scholar: lookup
      6. Hu CC, Yin J, Chau D, Cherwonogrodzky JW, Hu WG. Active immunity induced by passive IgG post-exposure protection against ricin.. Toxins (Basel) 2014 Jan 21;6(1):380-93.
        doi: 10.3390/toxins6010380pubmed: 24451844google scholar: lookup
      7. Baskaran P, Lehmann TE, Topchiy E, Thirunavukkarasu N, Cai S, Singh BR, Deshpande S, Thyagarajan B. Effects of enzymatically inactive recombinant botulinum neurotoxin type A at the mouse neuromuscular junctions.. Toxicon 2013 Sep;72:71-80.
        doi: 10.1016/j.toxicon.2013.06.014pubmed: 23810945google scholar: lookup
      8. Duncan MC, Linington RG, Auerbuch V. Chemical inhibitors of the type three secretion system: disarming bacterial pathogens.. Antimicrob Agents Chemother 2012 Nov;56(11):5433-41.
        doi: 10.1128/AAC.00975-12pubmed: 22850518google scholar: lookup
      Subscribe to our newsletter
      Join 99,344 horse owners like you who receive our email updates on horse health and nutrition.